2-BBB Medicines

Executive Summary

2-BBB Medicines is a Dutch biotechnology company leveraging its proprietary blood-brain barrier (BBB) targeting technology to enable CNS delivery of known therapeutics. Founded in 2012 and based in Leiden, the company combines established disease targets and compounds with its validated drug delivery platform, aiming to accelerate development for brain disorders. Its pipeline includes two clinical-stage programs: one for brain cancer and another for neuro-inflammatory diseases. By repurposing drugs with proven safety profiles and enhancing their brain penetration, 2-BBB reduces translational risk and development timelines. The company’s approach addresses a critical unmet need, as over 98% of small molecules and nearly all biologics fail to cross the BBB effectively. With a focused strategy and clinical proof-of-concept, 2-BBB is positioned to advance novel CNS therapies efficiently.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for lead brain cancer program40% success
• Q2 2027Initiation of Phase 2 trial for neuro-inflammatory disease program50% success
• TBDPotential partnership or licensing deal for BBB platform30% success